These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 1433632

  • 1. Complications of intravesical bacillus Calmette-Guerin: a case report.
    Gonzalez JA, Marcol BR, Wolf MC.
    J Urol; 1992 Dec; 148(6):1892-3. PubMed ID: 1433632
    [Abstract] [Full Text] [Related]

  • 2. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G.
    Wien Klin Wochenschr; 1987 Feb 20; 99(4):114-8. PubMed ID: 3577186
    [Abstract] [Full Text] [Related]

  • 3. Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Onur O, Celiker R.
    Clin Rheumatol; 1999 Feb 20; 18(1):74-6. PubMed ID: 10088958
    [Abstract] [Full Text] [Related]

  • 4. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.
    Bassi P.
    Surg Oncol; 2002 Jun 20; 11(1-2):77-83. PubMed ID: 12031870
    [Abstract] [Full Text] [Related]

  • 5. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL, DeHaven JI, Shriver J, Sarosdy MF.
    J Urol; 1991 Apr 20; 145(4):738-40. PubMed ID: 2005691
    [Abstract] [Full Text] [Related]

  • 6. Intravesical bacillus Calmette-Guérin and second primary malignancies.
    Guinan P, Brosman S, DeKernion J, Lamm D, Williams R, Richardson C, Reitsma D, Hanna M.
    Urology; 1989 May 20; 33(5):380-1. PubMed ID: 2711556
    [Abstract] [Full Text] [Related]

  • 7. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep 20; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 8. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
    Brosman SA, Lamm DL.
    J Urol; 1990 Aug 20; 144(2 Pt 1):313-5. PubMed ID: 2374197
    [Abstract] [Full Text] [Related]

  • 9. The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.
    van der Meijden PM, van Klingeren B, Steerenberg PA, de Boer LC, de Jong WH, Debruyne FM.
    J Urol; 1991 Aug 20; 146(2):444-6. PubMed ID: 1856950
    [Abstract] [Full Text] [Related]

  • 10. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL.
    J Urol; 1990 Dec 20; 144(6):1362-4. PubMed ID: 2231927
    [Abstract] [Full Text] [Related]

  • 11. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul 20; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 12. Pulmonary granulomata. A complication of intravesical administration of bacillus Calmette-Guerin for superficial bladder carcinoma.
    Smith RL, Alexander RF, Aranda CP.
    Cancer; 1993 Mar 01; 71(5):1846-7. PubMed ID: 8448747
    [Abstract] [Full Text] [Related]

  • 13. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1986 Oct 01; 136(4):820-4. PubMed ID: 3761438
    [Abstract] [Full Text] [Related]

  • 14. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
    Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM.
    J Urol; 1992 Mar 01; 147(3):596-600. PubMed ID: 1538436
    [Abstract] [Full Text] [Related]

  • 15. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1988 May 01; 139(5):935-40. PubMed ID: 3361667
    [Abstract] [Full Text] [Related]

  • 16. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ, Ratliff TL.
    Surg Annu; 1990 May 01; 22():363-78. PubMed ID: 2408170
    [No Abstract] [Full Text] [Related]

  • 17. Vesicoureteral reflux after intravesical instillation of bacillus Calmette-Guérin against carcinoma in situ of the bladder.
    Morita T, Tokue A.
    Urol Int; 2004 May 01; 73(3):287-8. PubMed ID: 15539855
    [Abstract] [Full Text] [Related]

  • 18. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ.
    J Urol; 1987 Aug 01; 138(2):295-8. PubMed ID: 3298694
    [Abstract] [Full Text] [Related]

  • 19. Intravesical Evans Bacille Calmette-Guérin in the treatment of carcinoma in situ.
    Cumming JA, Hargreave TB, Webb JN, McIntyre MA, Chisholm GD.
    Br J Urol; 1989 Mar 01; 63(3):259-63. PubMed ID: 2702423
    [Abstract] [Full Text] [Related]

  • 20. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA.
    Eur Urol; 2016 Jun 01; 69(6):1046-52. PubMed ID: 26803476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.